XNCR (Xencor, Inc.) Stock Financials & Earnings | Market Cap Arena

XNCR (Xencor, Inc.) Stock Financials & Earnings | Market Cap Arena

XNCRXencor, Inc.

Mkt Cap$890M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$126M

Net Income (TTM)-$92M

EPS (TTM)-$1.24

Free Cash Flow (TTM)-$138M

Gross Margin93.7%

Op. Margin-141.4%

Net Margin-73.2%

FCF Margin-110.1%

P/S Ratio (TTM)7.1x

P/E Ratio (TTM)—

YoY Rev Growth+4.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$19M	-$47M	-$61M
Q2 23	$46M	-$15M	-$26M
Q3 23	$59M	-$6M	-$18M
Q4 23	$51M	$48M	-$29M
Q1 24	$16M	$16M	-$55M
Q2 24	$17M	$14M	-$62M
Q3 24	$18M	$18M	-$55M
Q4 24	$70M	$70M	$4M
Q1 25	$33M	$30M	-$43M
Q2 25	$44M	$41M	-$33M
Q3 25	$21M	$21M	-$48M
Q4 25	$28M	$26M	-$54M

Valuation

Quarter	P/S	P/E
Q1 23	9.1x	—
Q2 23	7.8x	—
Q3 23	6.1x	—
Q4 23	5.1x	—
Q1 24	5.2x	—
Q2 24	6.2x	—
Q3 24	8.7x	—
Q4 24	7.4x	—
Q1 25	6.5x	—
Q2 25	5.4x	—
Q3 25	5.3x	—
Q4 25	7.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$31M	-$42M
Q2 23	-$38M	-$43M
Q3 23	-$27M	-$31M
Q4 23	$18M	$17M
Q1 24	-$55M	-$56M
Q2 24	-$67M	-$71M
Q3 24	-$26M	-$28M
Q4 24	-$56M	-$58M
Q1 25	-$16M	-$18M
Q2 25	-$36M	-$37M
Q3 25	-$31M	-$31M
Q4 25	-$52M	-$53M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$11M
Q2 23	$5M
Q3 23	$3M
Q4 23	$980K
Q1 24	$1M
Q2 24	$4M
Q3 24	$2M
Q4 24	$3M
Q1 25	$1M
Q2 25	$383K
Q3 25	$183K
Q4 25	$1M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-77.8%	+35.0%
Q2 23	+50.9%	+22.9%
Q3 23	+116.7%	+18.0%
Q4 23	+135.8%	+24.1%
Q1 24	-15.6%	-11.3%
Q2 24	-62.7%	+10.8%
Q3 24	-69.9%	-5.7%
Q4 24	+37.4%	-17.2%
Q1 25	+104.6%	+7.4%
Q2 25	+157.1%	-3.1%
Q3 25	+18.0%	-6.1%
Q4 25	-59.7%	+24.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$13M	66.4%
Q2 23	$14M	29.8%
Q3 23	$13M	21.8%
Q4 23	$0	0.0%
Q1 24	$11M	71.4%
Q2 24	$17M	101.4%
Q3 24	$12M	69.3%
Q4 24	$12M	17.6%
Q1 25	$0	0.0%
Q2 25	$11M	24.6%
Q3 25	$10M	48.1%
Q4 25	$10M	36.1%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$66M	$14M
Q2 23	$60M	$11M
Q3 23	$65M	$12M
Q4 23	$63M	$15M
Q1 24	$57M	$14M
Q2 24	$62M	$18M
Q3 24	$58M	$15M
Q4 24	$51M	$15M
Q1 25	$59M	$17M
Q2 25	$62M	$15M
Q3 25	$54M	$14M
Q4 25	$65M	$17M

Revenue Segments

Quarter	Milestone	Research collaboration	Royalty	License Agreement	Non-cash Royalty
Q1 23	$5M	$200K	$14M	—	—
Q2 23	$10M	$22M	$13M	—	—
Q3 23	$46M	—	$15M	—	—
Q2 24	—	—	—	$9M	$9M
Q1 25	$15M	—	$18M	—	—
Q2 25	$25M	—	$19M	—	—
Q3 25	—	—	$21M	—	—
Q4 25	$6M	—	$22M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$72M	$516M	$588M
Q2 23	$35M	$517M	$551M
Q3 23	$53M	$442M	$495M
Q4 23	$54M	$540M	$594M
Q1 24	$31M	$505M	$536M
Q2 24	$31M	$478M	$508M
Q3 24	$29M	$514M	$543M
Q4 24	$41M	$457M	$498M
Q1 25	$40M	$430M	$470M
Q2 25	$44M	$399M	$444M
Q3 25	$28M	$443M	$471M
Q4 25	$54M	$381M	$435M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	60M	-0.2%
Q2 23	60M	+0.1%
Q3 23	61M	+1.4%
Q4 23	61M	+0.4%
Q1 24	61M	+0.6%
Q2 24	62M	+0.8%
Q3 24	64M	+3.8%
Q4 24	73M	+14.3%
Q1 25	74M	+0.7%
Q2 25	74M	+0.8%
Q3 25	74M	+0.2%
Q4 25	74M	-0.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$244K	39
FY 15	$524K	53
FY 16	$1M	83
FY 17	$313K	114
FY 18	$260K	156
FY 19	$944K	166
FY 20	$607K	202
FY 21	$1M	254
FY 22	$586K	281
FY 23	$624K	280
FY 24	$442K	250
FY 25	$2K	75K